The short answer
Crataegus monogyna fruit extract lowered blood pressure in a small trial, so review a hawthorn product before taking it with lofexidine. The amount of any added low-pressure risk from the exact combination is unknown.
What this answer covers
Crataegus monogyna with plant part and preparation specified; fruit-extract findings are not automatically leaf, flower, berry-mixture or other-species findings.
- Supplement or preparation
- Crataegus monogyna
- Medication ingredient
- lofexidine
There is an exact-species human study
An eight-week placebo-controlled trial of Crataegus monogyna fruit concentrate found lower blood pressure. The study did not test lofexidine or show how often combined use would cause symptoms.
Match the plant part and extract
The trial used a specific aqueous fruit preparation. A label saying only hawthorn may describe a different species, plant part or blend. Ask your pharmacist to check the full product information.
Review use before the short treatment course
Lofexidine already lowers pressure and pulse. A longer hawthorn study cannot define safety over a short withdrawal-treatment course, and there is no proven protective dose gap. The treatment team should decide whether the supplement is appropriate.
What to do if you become lightheaded
If you feel dizzy or faint, sit or lie down. The lofexidine label tells outpatients with symptoms of low blood pressure or a slow pulse to withhold a dose and contact the prescriber for guidance. Follow your treatment team’s monitoring plan; do not make a permanent abrupt stop on your own.
Evidence and practical considerations
Side effects & toxicity
An exact-species fruit blood-pressure signal supports caution; added symptomatic hypotension with lofexidine has not been measured.
- Exact scope
- Crataegus monogyna with plant part and preparation specified; fruit-extract findings are not automatically leaf, flower, berry-mixture or other-species findings. with Oral lofexidine for adult opioid withdrawal; label section 11 supports hydrochloride-to-active-moiety identity.
- Medication form and route
- oral supplement unless clinician-directed electrolyte correction requires another route
- Timing or duration
- Lofexidine course is symptom-guided up to 14 days; longer supplement studies do not establish acute co-use safety.
What remains uncertain
- One small trial in hypertension, not opioid withdrawal. Product and species boundaries limit generalization.
Factors that may matter: exact preparation; blood pressure and pulse; kidney function; other medicines; baseline electrolyte status or alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults receiving treatment for opioid withdrawal symptoms.
Can cause hypotension, bradycardia, syncope and sedation. Avoid medicines lowering pulse or pressure; potentiates benzodiazepine CNS depression and is expected to potentiate other sedating drugs. Correct hypokalemia/hypomagnesemia first and monitor ECG at initiation in those patients because lofexidine prolongs QT. Abrupt discontinuation can raise blood pressure.
How this applies: RxNorm 28863 IN maps to this SPL; section 11 confirms salt-to-active-moiety identity. Applies to prescribed oral lofexidine for adult opioid withdrawal, not another alpha-2 agonist.
Does not establish supplement depletion, automatic supplementation, exact botanical interaction rates or a safe supplement spacing interval.
Source 2: original randomized controlled trial
jocms.org · Source check Sep 10, 2026
Population: 60 adults randomized with hypertension and sleep disorders; 56 represented in final tables.
Systolic and diastolic pressures were lower than placebo at eight weeks. Sleep scores did not differ between groups after treatment despite within-group improvement.
How this applies: Exact-species oral signal supporting cautious blood-pressure review; cannot quantify additive symptomatic hypotension.
No lofexidine. Small trial, baseline BMI and sleep-score imbalance, incomplete concomitant medication detail and internal tabular reporting inconsistencies. The specified fruit concentrate is not a leaf/flower extract or another Crataegus species.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Inspected sources applied to exact current available claim; no clinical review asserted. | |
| Research summary published |
Article revision: e2bdfecc0bdc5c59
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.